Abstract LB277: Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2)

培美曲塞 奥西默替尼 医学 肿瘤科 化疗 内科学 第一行 顺铂 癌症 腺癌 ROS1型
作者
Jincheng Yang,Damilola Olabode,Aarti Sawant,Karthick Vishwanathan,Srinivas Bachina,A. Todd,Dana Ghiorghiu,Yuri Rukazenkov,Alex Phipps,Diansong Zhou,Azar Shahraz
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): LB277-LB277
标识
DOI:10.1158/1538-7445.am2024-lb277
摘要

Abstract Osimertinib (Osi) is a potent, CNS-active irreversible inhibitor of epidermal growth factor receptor-mutate (EGFRm) and T790M mutations. It is currently approved as the standard of care in patients with locally advanced (Stage IIIB or IIIC) or metastatic (Stage IV) EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR-TKI therapy and as the first-line agent in patients with locally advanced or metastatic EGFRm NSCLC. FLAURA2 is a global, randomized, open-label, multi-center phase III clinical study to investigate the safety and efficacy of Osi 80 mg once daily in combination with platinum-pemetrexed chemotherapy compared to Osi monotherapy, as a first-line treatment in patients with locally advanced or metastatic EGFRm NSCLC. This study is ongoing and an sNDA has been submitted for approval. The objectives of this current analyses were to 1) assess the exposure-efficacy relationship between population PK model-derived Osi exposure metrics (AUCss, Cmaxss, Cminss), and PFS in patients from the investigational arm (Osi + chemotherapy arm, n=244) of FLAURA2 study and 2) assess the relationship between Osi exposure metrics and key safety endpoints. The exposure response (ER) relationship between Osi and progression free survival (PFS) in patients enrolled in the investigational arm of FLAURA2 was assessed. Kaplan Meier plots with patients stratified by quartile exposure of Osi in the investigational arm indicated no clear ER relationship, though there appears to be a trend of lower PFS with highest AUCss quartile. A stepwise Cox proportional hazard analysis indicated that the effect of Osi exposure metrics were not statistically significant associated with PFS; however, the number of pemetrexed cycles appeared to be a significant covariate on PFS. The relationship between Osi exposure metrics and AEs CTCAE Grade 3 and above causally related to Osi, as well as AESIs from the investigational arm of FLAURA2 study were explored. The graphical exploration and logistic regression analysis did not identify statistically significant relationship of Osi exposures on CTCAE ≥ Grade 3 adverse events (AEs) causally related to Osi, AEs leading to Osi dose interruptions/reductions/discontinuations, and AESIs including ≥ Grade 3 haematological AEs, cardiac effects, left ventricular ejection fraction decrease and ≥ Grade 1 interstitial lung disease causally related to Osi. In conclusions, no statistically significant relationships between exposure of Osi and response were observed, supporting the recommended dose of Osi of 80 mg daily in the FLAURA2 patient population. Overall, the recommended dose of Osi as monotherapy or in combination with chemotherapy is 80 mg once daily, with a dose reduction to 40 mg daily if unacceptable toxicity is observed. Citation Format: Jincheng Yang, Damilola Olabode, Aarti Sawant, Karthick Vishwanathan, Srinivas Bachina, Alexandar Todd, Dana Ghiorghiu, Yuri Rukazenkov, Alex Phipps, Diansong Zhou, Azar Shahraz. Exposure response and safety analysis of osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic NSCLC patients with EGFRm (FLAURA2) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB277.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在险峰发布了新的文献求助10
1秒前
正直的沛凝完成签到,获得积分10
1秒前
2秒前
3秒前
海鸥完成签到,获得积分10
3秒前
蒋若风完成签到,获得积分10
3秒前
爆米花应助孙文杰采纳,获得10
4秒前
小艾完成签到,获得积分10
4秒前
明理萃完成签到 ,获得积分10
5秒前
苏黎世发布了新的文献求助10
5秒前
6秒前
乔安发布了新的文献求助10
6秒前
炫哥IRIS发布了新的文献求助10
6秒前
LaTeXer给积极行天的求助进行了留言
7秒前
ww发布了新的文献求助10
7秒前
Carlo完成签到,获得积分10
8秒前
蓝胖子完成签到 ,获得积分10
9秒前
10秒前
终生科研徒刑完成签到 ,获得积分10
10秒前
11秒前
ysc发布了新的文献求助20
13秒前
14秒前
LKX完成签到 ,获得积分10
14秒前
纯真的诗兰完成签到,获得积分10
15秒前
自然函完成签到 ,获得积分10
15秒前
等一个晴天完成签到,获得积分10
16秒前
as发布了新的文献求助100
16秒前
天天快乐应助科研通管家采纳,获得10
16秒前
研友_VZG7GZ应助科研通管家采纳,获得10
16秒前
个性元枫应助科研通管家采纳,获得10
16秒前
kingwill应助科研通管家采纳,获得20
16秒前
顾矜应助科研通管家采纳,获得10
16秒前
16秒前
慕青应助科研通管家采纳,获得10
16秒前
今后应助科研通管家采纳,获得10
16秒前
隐形曼青应助科研通管家采纳,获得10
16秒前
Hello应助科研通管家采纳,获得10
16秒前
小蘑菇应助科研通管家采纳,获得10
16秒前
Ava应助科研通管家采纳,获得10
17秒前
海东来应助科研通管家采纳,获得30
17秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048